AMDL presents DR-70 prognosis data:
This article was originally published in Clinica
Latest results from the Cross Cancer Institute in Edmonton, Canada, indicate a prognostic value for AMDL's DR-70 cancer marker. AMDL claims that serum levels of DR-70 predict lung cancer survival. Patients with less than 7.25 ng/ml had a median survival of 55 weeks while those with more than 12 ng/ml survived only 17 weeks.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.